MF Researcher Database

Researcher Database

Advance
MATSUI Hiroshi
Heavy Ion Medical Center(Research Institute)
Lecturer
Last Updated :2025/03/26

Researcher Profile and Settings

Researcher

  • Name

    MATSUI Hiroshi

Affiliation

  • Heavy Ion Medical Center(Research Institute), Lecturer

Profile and Settings

  • Name

    Matsui, Hiroshi

Foreign language

  • Use in presentation

    English

  • Use in publication

    English

Affiliation

  • Gunma University, Lecturer
  • Gunma University, Lecturer

Affiliation

  • Affiliation

    Research Center fo Heavy Particle Beam Medicine

  • Job title

    Lecturer

Education

  • 2004, Gunma University Graduate School of Medicine, Department of Urology
  • 1995, Kochi Medical School, Faculty of Medicine
  • 2004, Gunma University
  • 1995, Kochi Medical School

Degree

  • Ph.D.
  • 条件付必須項目の入力がありません

Research Experience

  • Gunma University, Lecturer, Associate prof lecturer lv

Research Activities

Research Areas

  • Life sciences, Urology

Research Interests

  • prostate cancer
  • susceptibility gene
  • SNPs
  • familial prostate cancer

Published Papers

  • Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3, SUZUKI KAZUHIRO / ITO KAZUTO / YAMAMOTO TAKUMI / FUKABORI YOSHITATSU / KUROKAWA KOHEI / YAMANAKA HIDETOSHI / KOIKE HIDEKAZU / MATSUI HIROSHI / ONO YOSHIHIRO / HASUMI MASARU / NAKAZATO HARUKI / OKUGI HIRONOBU / SEKINE YOSHITAKA / OOKI KAZUNARI, Jun. 2002, Int J Cancer
  • Gene expression profiles in human BPH: utilization of laser-capture microdissection and quantitative real-time PCR, SUZUKI KAZUHIRO / YAMANAKA HIDETOSHI / MATSUI HIROSHI / HASUMI MASARU / ONO YOSHIHIRO / NAKAZATO HARUKI / KOIKE HIDEKAZU / ITO KAZUTO / FUKABORI YOSHITATSU / KUROKAWA KOHEI, Nov. 2001, Anticancer Res
  • Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia, MATSUMOTO KAZUHISA / SUZUKI KAZUHIRO / KOIKE HIDEKAZU / HASUMI MASARU / MATSUI HIROSHI / OKUGI HIRONOBU / SHIBATA YASUHIRO / ITO KAZUTO / YAMANAKA HIDETOSHI, Sep. 2003, Anticancer Res
  • Association of genetic polymorphisms of Glutathione-S-transpherase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population, NAKAZATO HARUKI / ITO KAZUTO / KUROKAWA KOHEI / YAMANAKA HIDETOSHI / SUZUKI KAZUHIRO / MATSUI HIROSHI / KOIKE HIDEKAZU / OKUGI HIRONOBU / OHTAKE NOBUAKI / TAKEI TOMOYUKI / NAKATA SEIJI / HASUMI MASARU, May 2003, Anticancer Res
  • A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese, SUZUKI KAZUHIRO / ITO KAZUTO / KUROKAWA KOHEI / YAMANAKA HIDETOSHI / MATSUI HIROSHI / OHTAKE NOBUAKI / NAKATA SEIJI / TAKEI TOMOYUKI / NAKAZATO HARUKI / OKUGI HIRONOBU / KOIKE HIDEKAZU / ONO YOSHIHIRO, Jul. 2003, J Biomed Sci
  • Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate cancer risk in a Japanese population, SUZUKI KAZUHIRO / ITO KAZUTO / YAMANAKA HIDETOSHI / NAKAZATO HARUKI / MATSUI HIROSHI / KOIKE HIDEKAZU / OKUGI HIRONOBU / KASHIWAGI BUNZOU / NISHII MASAHIRO / OHTAKE NIBUAKI / NAKATA SEIJI, Oct. 2003, Cancer
  • Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues, HASUMI MASARU / SUZUKI KAZUHIRO / MATSUI HIROSHI / KOIKE HIDEKAZU / ITO KAZUTO / YAMANAKA HIDETOSHI, Oct. 2003, Cancer Lett
  • Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study, SUZUKI KAZUHIRO / HATORI MOTOAKI / ITO KAZUTO / YAMANAKA HIDETOSHI / MATSUI HIROSHI / NAKAZATO HARUKI / KOIKE HIDEKAZU / OKUGI HIRONOBU / HASUMI MASARU / OHTAKE NOBUAKI / NAKATA SEIJI / TAKEI TOMOYUKI, Jun. 2003, Cancer Lett
  • Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population, SUZUKI KAZUHIRO / ITO KAZUTO / OHTAKE NOBUAKI / NAKATA SEIJI / TAKEI TOMOYUKI / MATSUI HIROSHI / ONO YOSHIHIRO / NAKAZATO HARUKI / HASUMI MASARU / KOIKE HIDEKAZU, Nov. 2002, Anticancer Res
  • Methylation status of insulin-like growth factor-binding protein-3 promoter in prostate cancer tissues., Hironobu Okugi, Hidekazu Koike, Yoshitaka Sekine, Hiroshi Matsui, Kauzhiro Suzuki, 2006, Asia-Pacific Journal of Clinical Oncology
  • Novel amino acid substitutional mutation, tyrosine-739-aspartic acid, in the androgen receptor gene in complete androgen insensitivity syndrome, SUZUKI KAZUHIRO / FUKABORI YOSHITATSU / NAKAZATO HARUKI / HASUMI MASARU / MATSUI HIROSHI / ITO KAZUTO / KUROKAWA KOHEI / YAMANAKA HIDETOSHI, Jun. 2001, Int J Androl
  • Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population., Koike H, Nakazato H, Ohtake N, Matsui H, Okugi H, Shibata Y, Nakata S, Yamanaka H, Suzuki K., Mar. 2008, Int Urol Nephrol.
  • Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor., Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K., Jul. 2008, Biochem Biophys Res Commun.
  • Association of 2 Common Chromosome 8q24 Variants, SNP rs1447295 and Microsatellite Marker DG8S737, With Familial Prostate Cancer and High Grade Disease in a Japanese Population. , Tatsuya Hamano,* Hiroshi Matsui,*,(* Equal study contribution.) Yoshitaka Sekine, Nobuaki Ohtake, Seiji Nakata and Kazuhiro Suzuki, Aug. 2010, J Urol.
  • Genomewide linkage analysis of familial prostate cancer in the Japanese population., Matsui H, Suzuki K, Ohtake N, Nakata S, Takeuchi T, Yamanaka H, Inoue I. , Jan. 2004, J Hum Genet.
  • Polymorphisms of DNA repair genes, XRCC1 and XRCC3, and susceptibility to familial prostate cancer in a Japanese population. , Hamano T, Matsui H, Ohtake N, Nakata S and Suzuki K. , Jan. 2008, Asia-Pacific Journal of Clinical Oncology 4(1):21-26, 2008.
  • Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. , Okamura K, Koike H, Sekine Y, Matsui H and Suzuki K. , Aug. 2009, Cancer Epidemiology
  • Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer., Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y, Suzuki K., Apr. 2011, J Urol.
  • Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation., Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K, Suzuki K., May 2012, Biochem Biophys Res Commun.
  • Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands., Nishii M, Nomura M, Sekine Y, Koike H, Matsui H, Shibata Y, Ito K, Oyama T, Suzuki K., Nov. 2012, J Androl.
  • Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer., Fukuma Y, Matsui H, Koike H, Sekine Y, Shechter I, Ohtake N, Nakata S, Ito K, Suzuki K., Dec. 2012, Prostate Cancer Prostatic Dis.
  • Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range, Ito, Kazuto; Miyakubo, Mai; Sekine, Yoshitaka; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Suzuki, Kazuhiro, 2013, WORLD JOURNAL OF UROLOGY
    DOI
  • 前立腺がんの重粒子線治療はどこまでエビデンスがあるのか?, 松井 博,加藤 弘之,神沼 拓也,伊藤 一人,鈴木 和浩,大野 達也, Nov. 2013, 12, 5, 515-521
  • YM155 reverses rapamycin resistance in renal cancer by decreasing survivin, Koike, Hidekazu; Nitta, Takashi; Sekine, Yoshitaka; Arai, Seiji; Furuya, Yosuke; Nomura, Masashi; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Oyama, Tetsunari; Suzuki, Kazuhiro, Oct. 2014, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    DOI
  • Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life, Ishikawa, Hitoshi; Katoh, Hiroyuki; Kaminuma, Takuya; Kawamura, Hidemasa; Ito, Kazuto; Matsui, Hiroshi; Hirato, Junko; Shimizu, Nobuaki; Takezawa, Yutaka; Tsuji, Hiroshi; Suzuki, Kazuhiro; Ohno, Tatsuya; Nakano, Takashi, Oct. 2015, ANTICANCER RESEARCH
  • A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer, Suzuki, Kazuhiro; Ozono, Seiichiro; Yamaguchi, Akito; Koike, Hidekazu; Matsui, Hiroshi; Nagata, Masao; Takubo, Takatoshi; Miyashita, Kana; Matsushima, Takafumi; Akaza, Hideyuki, 2015, CANCER CHEMOTHERAPY AND PHARMACOLOGY
    DOI
  • Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer, Kato, Haruo; Furuya, Yosuke; Miyazawa, Yoshiyuki; Miyao, Takeshi; Syuto, Takahiro; Nomura, Masashi; Sekine, Yoshitaka; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, Nov. 2016, ANTICANCER RESEARCH
    DOI
  • Germline Variants of Prostate Cancer in Japanese Families, Hayano, Takahide; Matsui, Hiroshi; Nakaoka, Hirofumi; Ohtake, Nobuaki; Hosomichi, Kazuyoshi; Suzuki, Kazuhiro; Inoue, Ituro, Oct. 2016, PLOS ONE
    DOI
  • A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients, Miyazawa, Yoshiyuki; Sekine, Yoshitaka; Syuto, Takahiro; Nomura, Masashi; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, 2017, BMC UROLOGY
    DOI
  • Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL, Fujizuka, Yuji; Ito, Kazuto; Oki, Ryo; Suzuki, Rie; Sekine, Yoshitaka; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Suzuki, Kazuhiro, 2017, INTERNATIONAL JOURNAL OF UROLOGY
    DOI
  • Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab, Miyazawa, Yoshiyuki; Sekine, Yoshitaka; Syuto, Takahiro; Nomura, Masashi; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, 2017, ANTICANCER RESEARCH
    DOI
  • Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content, Shibata, Yasuhiro; Arai, Seiji; Miyazawa, Yoshiyuki; Shuto, Takahiro; Nomura, Masashi; Sekine, Yoshitaka; Koike, Hidekazu; Matsui, Hiroshi; Ito, Kazuto; Suzuki, Kazuhiro, 2017, PROSTATE
    DOI
  • Suicide attempt with an overdose of sunitinib, Arai, Seiji; Matsui, Hiroshi; Ohki, Ryo; Miyazawa, Yoshiyuki; Koike, Hidekazu; Hashita, Tadahiro; Katsuyama, Yoshihiko; Sekine, Yoshitaka; Nomura, Masashi; Shibata, Yasuhiro; Hatori, Motoaki; Ito, Kazuto; Yamamoto, Koujirou; Ohmori, Shigeru; Suzuki, Kazuhiro, Oct. 2014, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    DOI
  • Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism, Sekine, Yoshitaka; Nakayama, Hiroshi; Miyazawa, Yoshiyuki; Kato, Haruo; Furuya, Yosuke; Arai, Seiji; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, 2018, ONCOLOGY LETTERS
    DOI
  • Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer, Miyazawa, Yoshiyuki; Sekine, Yoshitaka; Syuto, Takahiro; Nomura, Masashi; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, 2018, IN VIVO
    DOI
  • 家族性前立腺癌の遺伝子解析と臨床応用の可能性, 松井 博,大竹 伸明,中田 誠司,栗原 聰太,小池 秀和,鈴木 和浩 , 2016, 3, 1, 53-60
  • Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population, Okugi, Hironobu;Nakazato, Haruki;Matsui, Hiroshi;Ohtake, Nobuaki;Nakata, Seiji;Suzuki, Kazuhiro, 2006, CANCER DETECTION AND PREVENTION, 30, 3, 262, 268
    DOI
  • Polymorphisms of DNA repair genes, XRCC1 and XRCC3, and susceptibility to familial prostate cancer in a Japanese population, Hamano, Tatsuya;Matsui, Hiroshi;Ohtake, Nobuaki;Nakata, Seiji;Suzuki, Kazuhiro, 2008, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4, 1, 21, 26
    DOI
  • Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor, Sekine, Yoshitaka;Furuya, Yosuke;Nishii, Masahiro;Koike, Hidekazu;Matsui, Hiroshi;Suzuki, Kazuhiro, 2008, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 372, 2, 356, 361
    DOI
  • Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer, Okamura, Keigo;Koike, Hidekazu;Sekine, Yoshitaka;Matsui, Hiroshi;Suzuki, Kazuhiro, 2009, CANCER EPIDEMIOLOGY, 33, 2, 137, 141
    DOI
  • Association of SNP rs1447295 and Microsatellite Marker DG8S737 With Familial Prostate Cancer and High Grade Disease, Hamano, Tatsuya;Matsui, Hiroshi;Sekine, Yoshitaka;Ohtake, Nobuaki;Nakata, Seiji;Suzuki, Kazuhiro, 2010, JOURNAL OF UROLOGY, 184, 2, 738, 742
    DOI
  • Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation, Morikawa, Yasuyuki;Koike, Hidekazu;Sekine, Yoshitaka;Matsui, Hiroshi;Shibata, Yasuhiro;Ito, Kazuto;Suzuki, Kazuhiro, 2012, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 419, 3, 584, 589
    DOI
  • Luteinizing Hormone (LH)-Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands, Nishii, Masahiro;Nomura, Masashi;Sekine, Yoshitaka;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Ito, Kazuto;Oyama, Tetsunari;Suzuki, Kazuhiro, 2012, JOURNAL OF ANDROLOGY, 33, 6, 1233, 1238
    DOI
  • Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range, Ito, Kazuto;Miyakubo, Mai;Sekine, Yoshitaka;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Suzuki, Kazuhiro, 2013, WORLD JOURNAL OF UROLOGY, 31, 2, 305, 311
    DOI
  • A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients, Miyazawa, Yoshiyuki;Sekine, Yoshitaka;Syuto, Takahiro;Nomura, Masashi;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Ito, Kazuto;Suzuki, Kazuhiro, 2017, BMC UROLOGY, 17
    DOI
  • Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer, Miyazawa, Yoshiyuki;Sekine, Yoshitaka;Syuto, Takahiro;Nomura, Masashi;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Ito, Kazuto;Suzuki, Kazuhiro, 2018, IN VIVO, 32, 2, 409, 412
    DOI
  • Assessment of antimicrobiral prophylaxis in transperineal prostate biopsy: A single-center retrospective study of 485 cases, Baba, Kyoko;Sekine, Yoshitaka;Miyazawa, Yoshiyuki;Syuto, Takahiro;Nomura, Masashi;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Ito, Kazuto;Suzuki, Kazuhiro, 2018, JOURNAL OF INFECTION AND CHEMOTHERAPY, 24, 8, 637, 640
    DOI
  • Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening, Oki, Ryo;Ito, Kazuto;Suzuki, Rie;Fujizuka, Yuji;Arai, Seiji;Miyazawa, Yoshiyuki;Sekine, Yoshitaka;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Suzuki, Kazuhiro, 2018, INTERNATIONAL JOURNAL OF CANCER, 143, 7, 1611, 1619
    DOI
  • Clinical Outcomes and Survival Surrogacy Studies of PSA Declines and PSA kinetics Following Enzalutamide in Men with mCRPC, Miyazawa, Yoshiyuki;Miyao, Takeshi;Nakayama, Hiroshi;Kurihara, Sota;Oki, Ryo;Syuto, Takahiro;Sekine, Yoshitaka;Nomura, Masashi;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Ito, Kazuto;Suzuki, Kazuhiro, 2018, INTERNATIONAL JOURNAL OF UROLOGY, 25, 357, 357
  • Hypofractionated Intensity-modulated Radiotherapy for Intermediate- and High-risk Prostate Cancer: A Retrospective Study, Kubo, Nobuteru;Kawamura, Hidemasa;Oike, Takahiro;Sato, Hiro;Iwanaga, Mototaro;Mizukami, Tatsuji;Adachi, Akiko;Matsui, Hiroshi;Ito, Kazuto;Suzuki, Kazuhiro;Nakano, Takashi, 2019, IN VIVO, 33, 4, 1235, 1241
    DOI
  • An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression, Miyazawa, Yoshiyuki;Sekine, Yoshitaka;Shimizu, Nobuaki;Takezawa, Yutaka;Nakamura, Toshiyuki;Miyao, Takeshi;Nakayama, Hiroshi;Kurihara, Sota;Syuto, Takahiro;Nomura, Masashi;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Suzuki, Kazuhiro, 2019, PROSTATE, 79, 12, 1462, 1470
    DOI
  • Quality of life in prostate cancer patients receiving particle radiotherapy: A review of the literature, Kawamura, Hidemasa;Kubo, Nobuteru;Sato, Hiro;Miyasaka, Yuhei;Matsui, Hiroshi;Ito, Kazuto;Suzuki, Kazuhiro;Ohno, Tatsuya, 2020, INTERNATIONAL JOURNAL OF UROLOGY, 27, 1, 24, 29
    DOI
  • Exploratory study of prognostic factors in mCRPC patients who administered enzalutamide focusing on early PSA decline and PSA kinetics at PSA progression: Results of retrospective multicenter study., Miyazawa, Yoshiyuki;Shimizu, Nobuaki;Takezawa, Yutaka;Nakamura, Toshiyuki;Miyao, Takeshi;Nakayama, Hiroshi;Kurihara, Sota;Syuto, Takahiro;Nomura, Masashi;Sekine, Yoshitaka;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Suzuki, Kazuhiro, 2019, JOURNAL OF CLINICAL ONCOLOGY, 37, 7
  • Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702", Kawamura, Hidemasa;Kubo, Nobuteru;Sato, Hiro;Mizukami, Tatsuji;Katoh, Hiroyuki;Ishikawa, Hitoshi;Ohno, Tatsuya;Matsui, Hiroshi;Ito, Kazuto;Suzuki, Kazuhiro;Nakano, Takashi;Gunma Univ Heavy Ion Med Ctr, 2020, BMC CANCER, 20, 1
    DOI
  • A prospective study of the relationship between clinical outcomes of enzalutamide and serum androgen levels measured by LC-MS/MS in patients with CRPC, Miyazawa, Yoshiyuki;Miyao, Takeshi;Nakamura, Toshiyuki;Takezawa, Yutaka;Shimizu, Nobuaki;Matsuo, Yasushige;Ogura, Haruyuki;Takei, Tomoyuki;Oka, Daisuke;Arai, Seiji;Sekine, Yoshitaka;Koike, Hidekazu;Matsui, Hiroshi;Shibata, Yasuhiro;Suzuki, Kazuhiro, 2020, JOURNAL OF CLINICAL ONCOLOGY, 38, 6
  • Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer, Darwis, Narisa Dewi Maulany;Oike, Takahiro;Kawamura, Hidemasa;Kawahara, Masahiro;Kubo, Nobuteru;Sato, Hiro;Miyasaka, Yuhei;Katoh, Hiroyuki;Ishikawa, Hitoshi;Matsui, Hiroshi;Miyazawa, Yoshiyuki;Ito, Kazuto;Suzuki, Kazuhiro;Gondhowiardjo, Soehartati;Nakano, Takashi;Ohno, Tatsuya, 2020, CANCERS, 12, 3
    DOI

MISC

  • Polymorphisms of DNA repair genes, XRCC1 and XRCC3, and susceptibility to familial prostate cancer in a Japanese population, Tatsuya Hamano; Hiroshi Matsui; Nobuaki Ohtake; Seiji Nakata; Kazuhiro Suzuki, Mar. 2008, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4, 1, 21, 26
    DOI
  • Polymorphisms of DNA repair genes, XRCC1 and XRCC3, and susceptibility to familial prostate cancer in a Japanese population, Tatsuya Hamano; Hiroshi Matsui; Nobuaki Ohtake; Seiji Nakata; Kazuhiro Suzuki, Mar. 2008, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4, 1, 21, 26
    DOI
  • Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor, Yoshitaka Sekine; Yosuke Furuya; Masahiro Nishii; Hidekazu Koike; Hiroshi Matsui; Kazuhiro Suzuki, Jul. 2008, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 372, 2, 356, 361
    DOI
  • Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor, Yoshitaka Sekine; Yosuke Furuya; Masahiro Nishii; Hidekazu Koike; Hiroshi Matsui; Kazuhiro Suzuki, Jul. 2008, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 372, 2, 356, 361
    DOI
  • Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population, Hidekazu Koike; Haruki Nakazato; Nobuaki Ohtake; Hiroshi Matsui; Hironobu Okugi; Yasuhiro Shibata; Seiji Nakata; Hidetoshi Yamanaka; Kazuhiro Suzuki, Dec. 2008, INTERNATIONAL UROLOGY AND NEPHROLOGY, 40, 4, 947, 951
    DOI
  • Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population, Hidekazu Koike; Haruki Nakazato; Nobuaki Ohtake; Hiroshi Matsui; Hironobu Okugi; Yasuhiro Shibata; Seiji Nakata; Hidetoshi Yamanaka; Kazuhiro Suzuki, Dec. 2008, INTERNATIONAL UROLOGY AND NEPHROLOGY, 40, 4, 947, 951
    DOI
  • A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer, Kazuhiro Suzuki; Seiichiro Ozono; Akito Yamaguchi; Hidekazu Koike; Hiroshi Matsui; Masao Nagata; Takatoshi Takubo; Kana Miyashita; Takafumi Matsushima; Hideyuki Akaza, Feb. 2015, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 75, 2, 373, 380
    DOI
  • A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer, Kazuhiro Suzuki; Seiichiro Ozono; Akito Yamaguchi; Hidekazu Koike; Hiroshi Matsui; Masao Nagata; Takatoshi Takubo; Kana Miyashita; Takafumi Matsushima; Hideyuki Akaza, Feb. 2015, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 75, 2, 373, 380
    DOI
  • Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life, Hitoshi Ishikawa; Hiroyuki Katoh; Takuya Kaminuma; Hidemasa Kawamura; Kazuto Ito; Hiroshi Matsui; Junko Hirato; Nobuaki Shimizu; Yutaka Takezawa; Hiroshi Tsuji; Kazuhiro Suzuki; Tatsuya Ohno; Takashi Nakano, Oct. 2015, ANTICANCER RESEARCH, 35, 10, 5559, 5566
  • Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life, Hitoshi Ishikawa; Hiroyuki Katoh; Takuya Kaminuma; Hidemasa Kawamura; Kazuto Ito; Hiroshi Matsui; Junko Hirato; Nobuaki Shimizu; Yutaka Takezawa; Hiroshi Tsuji; Kazuhiro Suzuki; Tatsuya Ohno; Takashi Nakano, Oct. 2015, ANTICANCER RESEARCH, 35, 10, 5559, 5566
  • Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer, Keigo Okamura; Hidekazu Koike; Yoshitaka Sekine; Hiroshi Matsui; Kazuhiro Suzuki, Aug. 2009, CANCER EPIDEMIOLOGY, 33, 2, 137, 141
    DOI
  • Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer, Keigo Okamura; Hidekazu Koike; Yoshitaka Sekine; Hiroshi Matsui; Kazuhiro Suzuki, Aug. 2009, CANCER EPIDEMIOLOGY, 33, 2, 137, 141
    DOI
  • Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range, Kazuto Ito; Mai Miyakubo; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki, Apr. 2013, WORLD JOURNAL OF UROLOGY, 31, 2, 305, 311
    DOI
  • Luteinizing Hormone (LH)-Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands, Masahiro Nishii; Masashi Nomura; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Tetsunari Oyama; Kazuhiro Suzuki, Nov. 2012, JOURNAL OF ANDROLOGY, 33, 6, 1233, 1238
    DOI
  • Luteinizing Hormone (LH)-Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands, Masahiro Nishii; Masashi Nomura; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Tetsunari Oyama; Kazuhiro Suzuki, Nov. 2012, JOURNAL OF ANDROLOGY, 33, 6, 1233, 1238
    DOI
  • Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer, Y. Fukuma; H. Matsui; H. Koike; Y. Sekine; I. Shechter; N. Ohtake; S. Nakata; K. Ito; K. Suzuki, Dec. 2012, PROSTATE CANCER AND PROSTATIC DISEASES, 15, 4, 339, 345
    DOI
  • Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer, Y. Fukuma; H. Matsui; H. Koike; Y. Sekine; I. Shechter; N. Ohtake; S. Nakata; K. Ito; K. Suzuki, Dec. 2012, PROSTATE CANCER AND PROSTATIC DISEASES, 15, 4, 339, 345
    DOI
  • Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation, Yasuyuki Morikawa; Hidekazu Koike; Yoshitaka Sekine; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, Mar. 2012, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 419, 3, 584, 589
    DOI
  • Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation, Yasuyuki Morikawa; Hidekazu Koike; Yoshitaka Sekine; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, Mar. 2012, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 419, 3, 584, 589
    DOI
  • Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3, K Suzuki; H Koike; H Matsui; Y Ono; M Hasumi; H Nakazato; H Okugi; Y Sekine; K Oki; K Ito; T Yamamoto; Y Fukabori; K Kurokawa; H Yamanaka, Jun. 2002, INTERNATIONAL JOURNAL OF CANCER, 99, 6, 846, 852
    DOI
  • Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3, K Suzuki; H Koike; H Matsui; Y Ono; M Hasumi; H Nakazato; H Okugi; Y Sekine; K Oki; K Ito; T Yamamoto; Y Fukabori; K Kurokawa; H Yamanaka, Jun. 2002, INTERNATIONAL JOURNAL OF CANCER, 99, 6, 846, 852
    DOI
  • Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues, M Hasumi; K Suzuki; H Matsui; H Koike; K Ito; H Yamanaka, Oct. 2003, CANCER LETTERS, 200, 2, 187, 195
    DOI
  • Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues, M Hasumi; K Suzuki; H Matsui; H Koike; K Ito; H Yamanaka, Oct. 2003, CANCER LETTERS, 200, 2, 187, 195
    DOI
  • Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study, K Suzuki; H Matsui; H Nakazato; H Koike; H Okugi; M Hasumi; N Ohtake; S Nakata; T Takei; M Hatori; K Ito; H Yamanaka, Jun. 2003, CANCER LETTERS, 195, 2, 177, 183
    DOI
  • Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study, K Suzuki; H Matsui; H Nakazato; H Koike; H Okugi; M Hasumi; N Ohtake; S Nakata; T Takei; M Hatori; K Ito; H Yamanaka, Jun. 2003, CANCER LETTERS, 195, 2, 177, 183
    DOI
  • A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese, K Suzuki; H Matsui; N Ohtake; S Nakata; T Takei; H Nakazato; H Okugi; H Koike; Y Ono; K Ito; K Kurokawa; H Yamanaka, Jul. 2003, JOURNAL OF BIOMEDICAL SCIENCE, 10, 4, 430, 435
    DOI
  • A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese, K Suzuki; H Matsui; N Ohtake; S Nakata; T Takei; H Nakazato; H Okugi; H Koike; Y Ono; K Ito; K Kurokawa; H Yamanaka, Jul. 2003, JOURNAL OF BIOMEDICAL SCIENCE, 10, 4, 430, 435
    DOI
  • Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population, K Suzuki; H Nakazato; H Matsui; H Koike; H Okugi; B Kashiwagi; M Nishii; N Ohtake; S Nakata; K Ito; H Yamanaka, Oct. 2003, CANCER, 98, 7, 1411, 1416
    DOI
  • Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population, K Suzuki; H Nakazato; H Matsui; H Koike; H Okugi; B Kashiwagi; M Nishii; N Ohtake; S Nakata; K Ito; H Yamanaka, Oct. 2003, CANCER, 98, 7, 1411, 1416
    DOI
  • Genomewide linkage analysis of familial prostate cancer in the Japanese population, H Matsui; K Suzuki; N Ohtake; S Nakata; T Takeuchi; H Yamanaka; Inoue, I, Jan. 2004, JOURNAL OF HUMAN GENETICS, 49, 1, 9, 15
    DOI
  • Genomewide linkage analysis of familial prostate cancer in the Japanese population, H Matsui; K Suzuki; N Ohtake; S Nakata; T Takeuchi; H Yamanaka; Inoue, I, Jan. 2004, JOURNAL OF HUMAN GENETICS, 49, 1, 9, 15
    DOI
  • Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer, Haruo Kato; Yosuke Furuya; Yoshiyuki Miyazawa; Takeshi Miyao; Takahiro Syuto; Masashi Nomura; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, Nov. 2016, ANTICANCER RESEARCH, 36, 11, 6141, 6149
    DOI
  • Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer, Haruo Kato; Yosuke Furuya; Yoshiyuki Miyazawa; Takeshi Miyao; Takahiro Syuto; Masashi Nomura; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, Nov. 2016, ANTICANCER RESEARCH, 36, 11, 6141, 6149
    DOI
  • Survivin Is Associated With Cell Proliferation and Has a Role in 1a,25-Dihydroxyvitamin D-3 Induced Cell Growth Inhibition in Prostate Cancer, Hidekazu Koike; Yasuyuki Morikawa; Yoshitaka Sekine; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki, Apr. 2011, JOURNAL OF UROLOGY, 185, 4, 1497, 1503
    DOI
  • Survivin Is Associated With Cell Proliferation and Has a Role in 1a,25-Dihydroxyvitamin D-3 Induced Cell Growth Inhibition in Prostate Cancer, Hidekazu Koike; Yasuyuki Morikawa; Yoshitaka Sekine; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki, Apr. 2011, JOURNAL OF UROLOGY, 185, 4, 1497, 1503
    DOI
  • YM155 reverses rapamycin resistance in renal cancer by decreasing survivin, Hidekazu Koike; Takashi Nitta; Yoshitaka Sekine; Seiji Arai; Yosuke Furuya; Masashi Nomura; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Tetsunari Oyama; Kazuhiro Suzuki, Oct. 2014, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 140, 10, 1705, 1713
    DOI
  • YM155 reverses rapamycin resistance in renal cancer by decreasing survivin, Hidekazu Koike; Takashi Nitta; Yoshitaka Sekine; Seiji Arai; Yosuke Furuya; Masashi Nomura; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Tetsunari Oyama; Kazuhiro Suzuki, Oct. 2014, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 140, 10, 1705, 1713
    DOI
  • Suicide attempt with an overdose of sunitinib, Seiji Arai; Hiroshi Matsui; Ryo Ohki; Yoshiyuki Miyazawa; Hidekazu Koike; Tadahiro Hashita; Yoshihiko Katsuyama; Yoshitaka Sekine; Masashi Nomura; Yasuhiro Shibata; Motoaki Hatori; Kazuto Ito; Koujirou Yamamoto; Shigeru Ohmori; Kazuhiro Suzuki, Oct. 2014, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78, 4, 933, 935, Report scientific journal
    DOI
  • Suicide attempt with an overdose of sunitinib, Seiji Arai; Hiroshi Matsui; Ryo Ohki; Yoshiyuki Miyazawa; Hidekazu Koike; Tadahiro Hashita; Yoshihiko Katsuyama; Yoshitaka Sekine; Masashi Nomura; Yasuhiro Shibata; Motoaki Hatori; Kazuto Ito; Koujirou Yamamoto; Shigeru Ohmori; Kazuhiro Suzuki, Oct. 2014, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78, 4, 933, 935, Report scientific journal
    DOI
  • Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content, Yasuhiro Shibata; Seiji Arai; Yoshiyuki Miyazawa; Takahiro Shuto; Masashi Nomura; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Kazuto Ito; Kazuhiro Suzuki, May 2017, PROSTATE, 77, 6, 672, 680
    DOI
  • Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content, Yasuhiro Shibata; Seiji Arai; Yoshiyuki Miyazawa; Takahiro Shuto; Masashi Nomura; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Kazuto Ito; Kazuhiro Suzuki, May 2017, PROSTATE, 77, 6, 672, 680
    DOI
  • A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients, Yoshiyuki Miyazawa; Yoshitaka Sekine; Takahiro Syuto; Masashi Nomura; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, Aug. 2017, BMC UROLOGY, 17, 70
    DOI
  • Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL, Yuji Fujizuka; Kazuto Ito; Ryo Oki; Rie Suzuki; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki, Aug. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24, 8, 602, 609
    DOI
  • Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL, Yuji Fujizuka; Kazuto Ito; Ryo Oki; Rie Suzuki; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki, Aug. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24, 8, 602, 609
    DOI
  • Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab, Yoshiyuki Miyazawa; Yoshitaka Sekine; Takahiro Syuto; Masashi Nomura; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, Jul. 2017, ANTICANCER RESEARCH, 37, 7, 3667, 3671
    DOI
  • Germline Variants of Prostate Cancer in Japanese Families., Takahide Hayano; Hiroshi Matsui; Hirofumi Nakaoka; Nobuaki Ohtake; Kazuyoshi Hosomichi; Kazuhiro Suzuki; Ituro Inoue, 2016, PloS one, 11, 10, e0164233
    DOI
  • Germline Variants of Prostate Cancer in Japanese Families., Takahide Hayano; Hiroshi Matsui; Hirofumi Nakaoka; Nobuaki Ohtake; Kazuyoshi Hosomichi; Kazuhiro Suzuki; Ituro Inoue, 2016, PloS one, 11, 10, e0164233
    DOI
  • Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia, MATSUMOTO KAZUHISA; SUZUKI KAZUHIRO; KOIKE HIDEKAZU; HASUMI MASARU; MATSUI HIROSHI; OKUGI HIRONOBU; SHIBATA YASUHIRO; ITO KAZUTO; YAMANAKA HIDETOSHI, 2003, Anticancer Res, 23(5A):3767-3773
  • Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population, SUZUKI KAZUHIRO; ITO KAZUTO; OHTAKE NOBUAKI; NAKATA SEIJI; TAKEI TOMOYUKI; MATSUI HIROSHI; ONO YOSHIHIRO; NAKAZATO HARUKI; HASUMI MASARU; KOIKE HIDEKAZU, 2002, Anticancer Res, 22(6B):3507-3511
  • Association of genetic polymorphisms of Glutathione-S-transpherase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population, NAKAZATO HARUKI; ITO KAZUTO; KUROKAWA KOHEI; YAMANAKA HIDETOSHI; SUZUKI KAZUHIRO; MATSUI HIROSHI; KOIKE HIDEKAZU; OKUGI HIRONOBU; OHTAKE NOBUAKI; TAKEI TOMOYUKI; NAKATA SEIJI; HASUMI MASARU, 2003, Anticancer Res, 23(3C):2897-2902
  • Gene expression profiles in human BPH: utilization of laser-capture microdissection and quantitative real-time PCR, SUZUKI KAZUHIRO; YAMANAKA HIDETOSHI; MATSUI HIROSHI; HASUMI MASARU; ONO YOSHIHIRO; NAKAZATO HARUKI; KOIKE HIDEKAZU; ITO KAZUTO; FUKABORI YOSHITATSU; KUROKAWA KOHEI, 2001, Anticancer Res, 21(6A): 3861-3864
  • Novel amino acid substitutional mutation, tyrosine-739-aspartic acid, in the androgen receptor gene in complete androgen insensitivity syndrome, SUZUKI KAZUHIRO; FUKABORI YOSHITATSU; NAKAZATO HARUKI; HASUMI MASARU; MATSUI HIROSHI; ITO KAZUTO; KUROKAWA KOHEI; YAMANAKA HIDETOSHI, 2001, Int J Androl, 24(3):183-8
    DOI
  • Association of 2 Common Chromosome 8q24 Variants, SNP rs1447295 and Microsatellite Marker DG8S737, With Familial Prostate Cancer and High Grade Disease in a Japanese Population., Tatsuya Hamano; Hiroshi Matsui; Equal study contribution; Yoshitaka Sekine; Nobuaki Ohtake; Seiji Nakata; Kazuhiro Suzuki, 2010, J Urol., 184, 2, 738, 42
    DOI
  • Methylation status of insulin-like growth factor-binding protein-3 promoter in prostate cancer tissues, Hironobu Okugi; Hidekazu Koike; Yoshitaka Sekine; Hiroshi Matsui; Kazuhiro Suzuki, Sep. 2006, Asia-Pacific Journal of Clinical Oncology, 2, 3, 144, 149
    DOI
  • Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism, Yoshitaka Sekine; Hiroshi Nakayama; Yoshiyuki Miyazawa; Haruo Kato; Yosuke Furuya; Seiji Arai; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, 01 Mar. 2018, Oncology Letters, 15, 3, 3167, 3172
    DOI
  • Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range, Ito, Kazuto; Miyakubo, Mai; Sekine, Yoshitaka; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Suzuki, Kazuhiro, 2013, WORLD JOURNAL OF UROLOGY, 31, 2, 305, 311
    DOI
  • Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer, Miyazawa, Yoshiyuki; Sekine, Yoshitaka; Syuto, Takahiro; Nomura, Masashi; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, 2018, IN VIVO, 32, 2, 409, 412
    DOI
  • Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia, MATSUMOTO KAZUHISA; SUZUKI KAZUHIRO; KOIKE HIDEKAZU; HASUMI MASARU; MATSUI HIROSHI; OKUGI HIRONOBU; SHIBATA YASUHIRO; ITO KAZUTO; YAMANAKA HIDETOSHI, 2003, 23(5A):3767-3773
  • Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population, SUZUKI KAZUHIRO; ITO KAZUTO; OHTAKE NOBUAKI; NAKATA SEIJI; TAKEI TOMOYUKI; MATSUI HIROSHI; ONO YOSHIHIRO; NAKAZATO HARUKI; HASUMI MASARU; KOIKE HIDEKAZU, 2002, 22(6B):3507-3511
  • Association of genetic polymorphisms of Glutathione-S-transpherase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population, NAKAZATO HARUKI; ITO KAZUTO; KUROKAWA KOHEI; YAMANAKA HIDETOSHI; SUZUKI KAZUHIRO; MATSUI HIROSHI; KOIKE HIDEKAZU; OKUGI HIRONOBU; OHTAKE NOBUAKI; TAKEI TOMOYUKI; NAKATA SEIJI; HASUMI MASARU, 2003, 23(3C):2897-2902
  • Gene expression profiles in human BPH: utilization of laser-capture microdissection and quantitative real-time PCR, SUZUKI KAZUHIRO; YAMANAKA HIDETOSHI; MATSUI HIROSHI; HASUMI MASARU; ONO YOSHIHIRO; NAKAZATO HARUKI; KOIKE HIDEKAZU; ITO KAZUTO; FUKABORI YOSHITATSU; KUROKAWA KOHEI, 2001, 21(6A): 3861-3864
  • Novel amino acid substitutional mutation, tyrosine-739-aspartic acid, in the androgen receptor gene in complete androgen insensitivity syndrome, SUZUKI KAZUHIRO; FUKABORI YOSHITATSU; NAKAZATO HARUKI; HASUMI MASARU; MATSUI HIROSHI; ITO KAZUTO; KUROKAWA KOHEI; YAMANAKA HIDETOSHI, 2001, 24(3):183-8
    DOI
  • Association of 2 Common Chromosome 8q24 Variants, SNP rs1447295 and Microsatellite Marker DG8S737, With Familial Prostate Cancer and High Grade Disease in a Japanese Population., Tatsuya Hamano; Hiroshi Matsui; Equal study contribution; Yoshitaka Sekine; Nobuaki Ohtake; Seiji Nakata; Kazuhiro Suzuki, 2010, 184, 2, 738, 42
    DOI
  • Methylation status of insulin-like growth factor-binding protein-3 promoter in prostate cancer tissues, Hironobu Okugi; Hidekazu Koike; Yoshitaka Sekine; Hiroshi Matsui; Kazuhiro Suzuki, Sep. 2006, Asia-Pacific Journal of Clinical Oncology, 2, 3, 144, 149
    DOI
  • 前立腺がんの重粒子線治療はどこまでエビデンスがあるのか?, 松井 博; 加藤 弘之; 神沼 拓也; 伊藤 一人; 鈴木 和浩; 大野 達也, 2013, 12, 5, 515, 521
  • Evaluation of bone turnover/quality markers and bone mineral density in prostate cancer patients receiving androgen deprivation therapy with or without denosumab, Yoshiyuki Miyazawa; Syuto Takahiro; Sekine Yoshitaka; Masashi Nomura; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, 01 Jul. 2017, Anticancer Research, 37, 7, 3667, 3671
    DOI
  • Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism, Yoshitaka Sekine; Hiroshi Nakayama; Yoshiyuki Miyazawa; Haruo Kato; Yosuke Furuya; Seiji Arai; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, 01 Mar. 2018, Oncology Letters, 15, 3, 3167, 3172
    DOI
  • 家族性前立腺癌の遺伝子解析と臨床応用の可能性, 松井 博; 大竹 伸明; 中田 誠司; 栗原 聰太; 小池 秀和; 鈴木 和浩, 2016, 3, 1, 53, 60
  • A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients, Yoshiyuki Miyazawa; Yoshitaka Sekine; Takahiro Syuto; Masashi Nomura; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki, 29 Aug. 2017, BMC Urology, 17, 1, 70
    DOI
  • Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer, Miyazawa, Yoshiyuki; Sekine, Yoshitaka; Syuto, Takahiro; Nomura, Masashi; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro, 2018, 32, 2, 409, 412
    DOI

Presentations

  • Novel candidate gene for prostate cancer (PC) susceptibility, farnecyl-diphosphate farnecyltransferase 1 (FDFT1): Associations of FDFT1 gene variants with PC risk, and FDFT1 protein function evaluation in PC cells., American Urological Assoication, 2010
  • A novel candidate gene of susceptibility to prostate cancer, farnecyl-diphosphate farnecyltransferase 1 (FDFT1) gene: association between the variants of the FDFT1 gene and the prostate cancer risk, and the evaluation of the FDFT1 protein function to ・・・, European Association of Urology, 2010
  • Genomewide linkage analysis of familial prostate cancer in the Japanese population., American Urological Association, 2004
  • 家族性前立腺癌責任遺伝子の候補: farnesyl-diphosphate farnesyltransferase 1(FDFT1) 遺伝子多型と機能解析についての検討．, 日本泌尿器科学会総会 2010, 2010
  • 短期内分泌療法に伴う認知機能およびQOL評価, 日本泌尿器科東部学会総会 2009, 2009
  • 日本人前立腺癌における疾患関連遺伝子座8q24の検討, 日本泌尿器科学会東部総会 2008, 2008
  • 日本人の家族性および遺伝性前立腺癌におけるMacrophage Scavenger Receptor 1(MSR1)の遺伝子多型の検討, 前立腺癌ワークショップ 2007, 2007
  • 本邦の家族性前立腺癌における全ゲノム罹患同胞対連鎖解析, 日本泌尿器科学会総会 2004, 2004
  • 日本人の家族性前立腺癌における全ゲノム罹患同胞対連鎖解析, 第15回前立腺がんワークショップ, 2004
  • シロドシンによる排尿障害の治療：Urief Dose-Up and QOL Study, 日本泌尿器科学会総会 2009, 2009
  • Novel candidate gene for prostate cancer (PC) susceptibility, farnecyl-diphosphate farnecyltransferase 1 (FDFT1): Associations of FDFT1 gene variants with PC risk, and FDFT1 protein function evaluation in PC cells., American Urological Assoication, 2010
  • A novel candidate gene of susceptibility to prostate cancer, farnecyl-diphosphate farnecyltransferase 1 (FDFT1) gene: association between the variants of the FDFT1 gene and the prostate cancer risk, and the evaluation of the FDFT1 protein function to ・・・, European Association of Urology, 2010
  • Genomewide linkage analysis of familial prostate cancer in the Japanese population., American Urological Association, 2004
  • 日本人家族性前立腺癌におけるGWASによって同定された遺伝子多型群の検討, 日本家族性腫瘍学会, 2013
  • 前立腺癌に対する重粒子線治療後の有害事象評価としての尿流量測定および残尿測定の検討, 第101回日本泌尿器科学会総会, 2013
  • 前立腺癌に対する重粒子線治療後の有害事象評価としての尿流量測定および残尿測定の検討, 第50回日本癌治療学会学術集会, 2012
  • 家族性前立腺癌の臨床と基礎, 第21回日本腎泌尿器疾患予防医学研究会総会, 2012
  • 前立腺癌の遺伝的素因：前立腺癌責任遺伝子の同定, 第20回日本腎泌尿器疾患予防医学研究会総会, 2011
  • 当院における進行性腎細胞癌に対するSunitinibの使用経験, 2011

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.